Assessment of patient-reported outcomes (PROs) and longer-term adverse events (AEs) in phase I study of 225Ac-J591-PSMA for metastatic castration-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Nauseef, Jones T.
Thomas, Charlene
Ho, Benedict
Zuloaga, Juana Martinez
Gonzalez, Brian D.
Sun, Michael
Sartor, A. Oliver
Singh, Sharon
Bissassar, Mahelia
Fernandez, Escarleth
Tan, Angela
Patel, Amie
Naiz, Muhammad Obaid
Vallabhajosula, Shankar
Molina, Ana M.
Sternberg, Cora N.
Nanus, David M.
Osborne, Joseph
Bander, Neil Harrison
Tagawa, Scott T.
机构：
[1] New York Presbyterian Hosp, Weill Cornell Med Ctr, New York, NY USA
[2] Weill Cornell Med, New York, NY USA
[3] Cornell Univ, Ithaca, NY USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] Tulane Med Sch, Sch Med, New Orleans, LA USA
[6] Weill Cornell Med Ctr, New York, NY USA
[7] Weill Cornell Med, Englander Inst Precis Med, Hematol Oncol, New York, NY USA
[8] Sandra & Edward Meyer Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.077
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
77
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Phase I study of 225Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Sun, Michael
    Sartor, A. Oliver
    Thomas, Charlene
    Singh, Sharon
    Bissassar, Mahelia
    Fernandez, Escarleth
    Niaz, Muhammad Junaid
    Ho, Benedict
    Vallabhajosula, Shankar
    Babich, John
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Osborne, Joseph
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Osborne, Joseph
    Fernandez, Escarleth
    Thomas, Charlene
    Niaz, Muhammad Junaid
    Ciriaco, Amy
    Vallabhajosula, Shankar
    Vlachostergios, Panagiotis J.
    Molina, Ana M.
    Sternberg, Cora N.
    Singh, Sharon
    Babich, John
    Nanus, David M.
    Ballman, Karla, V
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Phase I dose-escalation study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Vallabhajosula, Shankar
    Jhanwar, Yuliya
    Ballman, Karla V.
    Hackett, Amy
    Emmerich, Lauren
    Babich, John
    Sartor, A. Oliver
    Harshman, Lauren Christine
    Beltran, Himisha
    Molina, Ana M.
    Nanus, David M.
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [4] Phase I/II study of 225Ac-J591 plus 177Lu-PSMA-I&T for progressive metastatic castration-resistant prostate cancer
    Nauseef, Jones T.
    Osborne, Joseph
    Gregos, Peter
    Thomas, Charlene
    Bissassar, Mahelia
    Singh, Sharon
    Patel, Amie
    Tan, Angela
    Naiz, Muhammad Obaid
    Zuloaga, Juana Martinez
    Chamberlain, Tessa
    Earle, Kara
    Wunder, Rebecca
    Nagar, Himanshu
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Bander, Neil Harrison
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC)
    Tagawa, Scott T.
    Osborne, Joseph
    Niaz, Muhammad Junaid
    Vallabhajosula, Shankar
    Vlachostergios, Panagiotis J.
    Thomas, Charlene
    Molina, Ana M.
    Sternberg, Cora N.
    Singh, Sharon
    Fernandez, Escarleth
    Babich, John
    Nanus, David M.
    Ballman, Karla V.
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [6] IS THERE A RELATIONSHIP BETWEEN PATIENT-REPORTED OUTCOMES (PROS) AND CLINICAL OUTCOMES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) POST-DOCETAXEL?
    Traina, S.
    Li, T.
    Johnson, K.
    Ho, K. F.
    Molina, A.
    Cella, D.
    VALUE IN HEALTH, 2015, 18 (07) : A470 - A470
  • [7] A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).
    Sun, Michael
    Nauseef, Jones T.
    Lebenthal, Justin M.
    Niaz, Muhammad Junaid
    Singh, Sharon
    Chamberlain, Tessa A.
    Bissassar, Mahelia
    Patel, Amie
    Tan, Angela
    Vallabhajosula, Shankar
    Babich, John
    Christos, Paul J.
    Osborne, Joseph
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Bander, Neil Harrison
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [8] A phase I/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC) in patients with prior treatment with 177Lu-PSMA.
    Nauseef, Jones T.
    Sun, Michael Philip
    Thomas, Charlene
    Bissassar, Mahelia
    Patel, Amie
    Tan, Angela
    Fernandez, Escarleth
    Davidson, Zachary
    Chamberlain, Tessa
    Earle, Kara
    Wunder, Rebecca
    Castellanos, Sandra Huicochea
    Gregos, Peter
    Osborne, Joseph
    Ballman, Karla V.
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Bander, Neil Harrison
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [9] Phase I/II trial of pembrolizumab and AR signaling inhibitor +/-225Ac-J591 for chemo-naive metastatic castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Osborne, Joseph
    Dallos, Matthew
    Nauseef, Jones
    Sternberg, Cora N.
    Gregos, Peter
    Patel, Amie
    Tan, Angela
    Singh, Sharon
    Bissassar, Mahelia
    Molina, Ana M.
    Giannakakou, Paraskevi
    Beltran, Himisha
    Nanus, David M.
    Ballman, Karla V.
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [10] ANALYSIS OF THE RELATIONSHIP BETWEEN PATIENT-REPORTED OUTCOMES (PROS) AND CLINICAL OUTCOMES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS WITHOUT PRIOR CHEMOTHERAPY
    Traina, S.
    Li, T.
    Johnson, K.
    Ho, K. F.
    Molina, A.
    Cella, D.
    VALUE IN HEALTH, 2015, 18 (07) : A335 - A336
12345